Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 117Cyclophosphamide 109pembrolizumab 88Radiotherapy 83Nivolumab 73Cisplatin 68fludarabine 65Biopsy 60Carboplatin 59Standard of Care 49Radiosurgery 45Gemcitabine 44Paclitaxel 42Dexamethasone 42Radiation 39Doxorubicin 39Rituximab 38Blood Specimen Collection 37Bevacizumab 37venetoclax 36Cytarabine 36Surveys and Questionnaires 35fludarabine phosphate 33Capecitabine 33Temozolomide 31Radiotherapy, Intensity-Modulated 31Practice Guidelines as Topic 31Ipilimumab 28Interviews as Topic 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡